CREPT downregulation reversed this process by reducing Bcl-2 and cIAP1 expression, upregulating caspase 3 and Bax expression, and inhibiting cell survival and tumor progression in lymphoma cells through the NF-kB signaling pathway. The gene discussed is RPRD1B; the disease is neoplasm.